Founded in 2013, Aphria is integrating their growing expertise with Health Canada`s new Access to Cannabis for Medical Purposes Regulations (ACMPR) for the medicinal marijuana industry. Possessing greenhouse related growing experience in plant and produce related expertise since 1943, Aphria is positioned to be an industry leader in providing patients with the highest quality medical marijuana. Aphria has developed integrated greenhouse growing solutions specifically focused on quality production of cannabis. With the authorization of quantity scale marijuana growing, Aphria greenhouse operations are a natural fit. Aphria is a licensed producer of Medicinal Marijuana under the Health Canada Regulations. Grown in Greenhouses, Aphria offers premium medical grade cannabis. Located in Leamington in Southwestern Ontario, the heart of the greenhouse-producing sector for plant and produce, Aphria is built from a lengthy background of greenhouse growing and business experience.
TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.
Midwest Eye Consultants provides total eye care from eye health exams to the treatment of eye diseases. See our locations page to find an office near you.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the-counter (OTC) remedies. We market our products in more than 165 countries and territories, and every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world. Mylans mission is grounded in our belief that every person matters and should have the opportunity to live the healthiest life possible. We have built our business model consistent with this belief, and through it, we are impacting people around the world with each passing year. Providing universal access to medicine is the core purpose of our model. To provide access, we must be able to satisfy the needs of an incredibly diversified global marketplace whose economic and political systems, approaches to delivering and paying for healthcare, languages and traditions, and customer and patient requirements vary by location and over time.